FolioLanternBeta
DYNDyne Therapeutics, Inc.

Erick Lucera

Chief Financial Officer at Dyne Therapeutics, Inc., as of Aug 17, 2026Sold $229K of stock in the past 12 months: 79% under a disclosed plan and 21% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
13K
shares held after the latest filing, Dyne Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
11K
shares sold, past 12 months
4
days with sales
$107K
largest single day, Apr 1, 2026
1
company filed for

Share of stake sold at Dyne Therapeutics, Inc. is not shown: most of their shares vested during the period, so a percentage would mislead. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarApr 2026: $107K under a disclosed plan$107KAprMay 2026: $27K under a disclosed planMayJun 2026: $48K to cover taxesJunJulAug 2026: $47K under a disclosed planAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Dyne Therapeutics, Inc. (DYN)Chief Financial OfficerApr 1, 2025Aug 17, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.